Emcure Pharmaceuticals Ltd (EMCURE) — shareholding pattern, promoter holding, financials and share price
About Emcure Pharmaceuticals Ltd (EMCURE)
Emcure Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as EMCURE and on the BSE under scrip code 544210. Its ISIN is INE168P01015.
Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally [1]
Emcure Pharmaceuticals is an Indian pharmaceutical company that develops and markets a broad range of pharmaceutical products worldwide, covering major therapeutic areas. It is strongly positioned in acute and chronic segments, such as gynecology, cardiovascular, oncology, and biologics.
Emcure has entered into a notable partnership with Novo Nordisk to introduce an exclusive semaglutide drug, a major step in its biotechnology endeavors. This collaboration is expected to drive significant growth and visibility in the innovative drug market.
Listed peers in Pharmaceuticals: Glaxosmithkline Pharmaceuticals Ltd, Gland Pharma Ltd, J B Chemicals & Pharmaceuticals Ltd, Wockhardt Ltd, Acutaas Chemicals Ltd, Sai Life Sciences Ltd.
Valuation & Returns
10 Jul 2026At ₹1,807.1 a share on 10 Jul 2026, Emcure Pharmaceuticals Ltd (EMCURE) was valued at a price-to-earnings ratio of 36.42x against an industry P/E of 36.41x and a price-to-book of 7.71x on a book value of ₹234.4 per share as of Mar 2025. Solomo computes return on equity of 21.17% and return on capital employed of 26.16% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 36.42x
- Industry P/E
- 36.41x
- P/B
- 7.71x
- EPS (TTM)
- ₹49.62
- Book value / share
- ₹234.4
- ROE
- 21.17%
- ROCE
- 26.16%
- ROA
- 11.43%
- Debt / equity
- 0.23x
- Dividend yield
- 0.17%
- EBITDA margin
- 20.06%
- 52-week range
- ₹1,260.1 – ₹1,944
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Emcure Pharmaceuticals Ltd (EMCURE) reported revenue of ₹9,204 crore, net profit of ₹941 crore and earnings per share of ₹48.76. That compares with revenue of ₹7,896 crore and net profit of ₹707 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹2,470 crore and net profit ₹244 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 5,855 | 5,986 | 6,658 | 7,896 | 9,204 |
| Net profit (₹ cr) | 703 | 562 | 528 | 707 | 941 |
| EPS (₹) | 36.62 | 29.42 | 27.5 | 35.96 | 48.76 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 13.02% | 8.96% | 18.59% |
| Profit growth | 12.60% | -10.80% | 34.10% |
| Stock price CAGR | - | - | 32% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 77.83% of Emcure Pharmaceuticals Ltd (EMCURE) (down 0.04 pp QoQ), foreign institutional investors (FII) hold 4.88% and domestic institutional investors (DII) hold 8.46%. Market capitalisation was ₹34,277 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2024.
Largest disclosed public shareholders in Jun 2026: Kotak Midcap Fund 1.93%, Aditya Birla Sun Life Trustee Private Limited A/C - Aditya Birla Sun Life Elss Tax Saver Fund 1.44%, Nippon Life India Trustee Ltd-A/C Nippon India Multi Cap Fund 1.33%, Government Pension Fund Global 1.05%, Hdfc Life Insurance Company Limited 1.03%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 77.83% | - | 4.88% | 8.46% | 22.17% |
| Mar 2026 | 77.87% | - | 3.35% | 6.1% | 22.13% |
| Dec 2025 | 77.87% | - | 3.59% | 6.1% | 22.13% |
| Sep 2025 | 77.88% | - | 3.29% | 4.37% | 22.12% |
| Jun 2025 | 77.91% | - | 2.86% | 2.84% | 22.09% |
| Mar 2025 | 77.92% | - | 3.07% | 3.44% | 22.08% |
| Dec 2024 | 77.94% | - | 3.05% | 3.87% | 22.06% |
| Sep 2024 | 78.08% | - | 2.91% | 3.96% | 21.92% |